Notícias

Investing.com -- Shares of psychedelic drug developers are surging premarket on Thursday after Eli Lilly announced a definitive agreement to acquire AtaiBeckley Inc., validating the sector and lifting sentiment across the space.

Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.

Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker’s recent buying spree.

Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing a recent buying spree. Eli will pay $6.75 a share in cash for the biopharma company, a 26% premium to yesterday's closing price of $5.

The deal gives Lilly access to a DMT-based nasal spray for treatment-resistant depression that has received FDA Breakthrough Therapy Designation

The radiopharma specialist will use earnings from this mega-round to progress ADVC001 and build manufacturing infrastructure to prepare for potential commercialisation.

GH Research (NASDAQ:GHRS) shares climbed around 12% in premarket trading on Thursday after reports that Eli Lilly (NYSE:LLY) is in discussions to acquire psychedelic drug developer Atai Life Sciences (NASDAQ:ATAI), a development that sparked renewed investor interest across the sector. Potential acquisition lifts sentiment across psychedelic drug developersThe reported takeover talks sent Atai shares soaring by as much as 53% before the opening bell, with investors speculating that increased pha

AtaiBeckley (NASDAQ:ATAI) shares jumped as much as 53% in premarket trading on Thursday after reports emerged that Eli Lilly (NYSE:LLY) is in discussions to acquire the psychedelic drug developer. Potential deal would broaden Lilly’s neuroscience portfolioAccording to BMO Capital Markets analyst Evan David Seigerman, an acquisition of AtaiBeckley would strengthen Eli Lilly’s presence in psychiatry while supporting its strategy of expanding beyond its established cardiometabolic business.

Psychedelic drugmaker AtaiBeckley was surging 50% ahead of the open Thursday following a report that pharma giant Eli Lilly is nearing a deal to buy the company . A deal, being negotiated at a premium, could be announced as early as this week, Bloomberg reported, citing people familiar with the matter. The shares jumped 22% in a single day in April when President Donald Trump signed a directive to accelerate the Food and Drug Administration’s review of psychedelic drugs for serious mental illnesses.

Faced with the dual pressures of shifting consumer habits and emerging health trends, General Mills finds itself in a challenging market position.

VC Magnus Sigurdsson said a rival bidder is unlikely after AtaiBeckley’s months-long structured sale process.

Eli Lilly is nearing an agreement involving AtaiBeckley, Bloomberg reported on Wednesday, citing people familiar with the matter.

Wegovy Pill Wins Big as Eli Lilly Rollout Lags

Wegovy captured about 89% of weekly prescriptions.

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the

Oral Wegovy is now cleared in all EU member states.

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State

Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.

BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.

The milestone payment strengthens VivoSim’s cash position while management projects significant revenue growth driven by expanding demand for its human-based preclinical testing platform. Key Investor TakeawaysVivoSim (NASDAQ:VIVS) received a $5 million milestone payment from Eli Lilly tied to the advancement of a previously sold drug candidate into Phase 2 studies.

Management jacked up its forecast in a way that's impossible to ignore, and while the stock has already ripped higher, the real debate is whether this is a new reality or a temporary sugar high.

(Bloomberg) -- AdvanCell Pty, a biotechnology firm backed by Eli Lilly & Co., has raised $315 million in new funding, underscoring investor confidence in its experimental cancer therapy.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsTrump Drops 20% Fee for Hormuz Cargo After Gulf PressureUS Hits Iran With Strikes, Blockade as Trump Plans Hormuz ChargeOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI Companion‘We Faltered’: IBM Plunges M

FDA grants full approval to Eli Lilly's selpercatinib (Retevmo) for a wider group of adult and pediatric patients with RET fusion solid tumors. The decision shifts selpercatinib from accelerated to traditional approval and broadens its labeled use across multiple tumor types. The update reinforces Eli Lilly's (NYSE:LLY) position in oncology and opens new commercial and clinical avenues for the drug. Eli Lilly, known for its oncology and biopharma portfolio, now has a fully approved RET...

Since its obesity pill Foundayo hit the market in April, Lilly has captured about 11% of the prescription volume for new pills, according to the latest weekly data. Novo Nordisk’s Wegovy pill, which launched in January, commands the rest. It is a remarkable turn of events for the near $80 billion anti-obesity market, among the hottest in the industry.

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -2.48% change compared to its last close.

Eli Lilly and Company (LLY) on Tuesday received traditional approval from the US Food and Drug Admin

The presentation on Biogen’s experimental Alzheimer’s treatment at a medical meeting Tuesday was supposed to boost confidence in its drug’s prospects. Instead, Biogen stock is down 6%, to $197. Tuesday’s presentation on the drug diranersen, at London’s Alzheimer’s Association International Conference, left attendees confused about what to conclude from Biogen’s Phase 2 study known as CELIA.

In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.

BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.

While the company's AI spending commands attention, the real story is how the technology is already accelerating the core business that funds it all.